176 related articles for article (PubMed ID: 12880373)
41. Where are we heading to in pharmacological IBD therapy?
Rogler G
Pharmacol Res; 2015 Oct; 100():220-7. PubMed ID: 26277232
[TBL] [Abstract][Full Text] [Related]
42. [Expression of zinc finger protein A20 in pediatric inflammatory bowel disease].
Zheng CF; Huang Y
Zhonghua Er Ke Za Zhi; 2011 Apr; 49(4):261-5. PubMed ID: 21624200
[TBL] [Abstract][Full Text] [Related]
43. [Cytokines in the pathogenesis of inflammatory bowel diseases].
José León A; Garrote JA; Arranz E
Med Clin (Barc); 2006 Jun; 127(4):145-52. PubMed ID: 16831396
[TBL] [Abstract][Full Text] [Related]
44. [Gene therapy with interleukin 10 in Crohn's disease: too early yet].
Dijkstra G; Hospers GA; Kleibeuker JH
Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2153-6. PubMed ID: 14626830
[TBL] [Abstract][Full Text] [Related]
45. Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation.
Autenrieth IB; Bucheler N; Bohn E; Heinze G; Horak I
Gut; 1997 Dec; 41(6):793-800. PubMed ID: 9462212
[TBL] [Abstract][Full Text] [Related]
46. Role of cytokines in the pathogenesis of inflammatory bowel disease.
Papadakis KA; Targan SR
Annu Rev Med; 2000; 51():289-98. PubMed ID: 10774465
[TBL] [Abstract][Full Text] [Related]
47. New mediators of immunity and inflammation in inflammatory bowel disease.
Monteleone G; Fina D; Caruso R; Pallone F
Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
[TBL] [Abstract][Full Text] [Related]
48. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
Fedorak RN; Gangl A; Elson CO; Rutgeerts P; Schreiber S; Wild G; Hanauer SB; Kilian A; Cohard M; LeBeaut A; Feagan B
Gastroenterology; 2000 Dec; 119(6):1473-82. PubMed ID: 11113068
[TBL] [Abstract][Full Text] [Related]
49. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
Sato T; Kanai T; Watanabe M; Sakuraba A; Okamoto S; Nakai T; Okazawa A; Inoue N; Totsuka T; Yamazaki M; Kroczek RA; Fukushima T; Ishii H; Hibi T
Gastroenterology; 2004 Mar; 126(3):829-39. PubMed ID: 14988837
[TBL] [Abstract][Full Text] [Related]
50. Gut inflammation: current update on pathophysiology, molecular mechanism and pharmacological treatment modalities.
Gyires K; Tóth ÉV; Zádori SZ
Curr Pharm Des; 2014; 20(7):1063-81. PubMed ID: 23782146
[TBL] [Abstract][Full Text] [Related]
51. Extraintestinal considerations in inflammatory bowel disease.
Levine JB; Lukawski-Trubish D
Gastroenterol Clin North Am; 1995 Sep; 24(3):633-46. PubMed ID: 8809240
[TBL] [Abstract][Full Text] [Related]
52. A new lactobacilli in vivo expression system for the production and delivery of heterologous proteins at mucosal surfaces.
Allain T; Mansour NM; Bahr MM; Martin R; Florent I; Langella P; Bermúdez-Humarán LG
FEMS Microbiol Lett; 2016 Jul; 363(13):. PubMed ID: 27190148
[TBL] [Abstract][Full Text] [Related]
53. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
Ogata H; Hibi T
Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
[TBL] [Abstract][Full Text] [Related]
54. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease.
Epstein J; Docena G; MacDonald TT; Sanderson IR
Br J Nutr; 2010 Mar; 103(6):824-32. PubMed ID: 19878610
[TBL] [Abstract][Full Text] [Related]
55. Hypoxia inducible factor-1α-induced interleukin-33 expression in intestinal epithelia contributes to mucosal homeostasis in inflammatory bowel disease.
Sun M; He C; Wu W; Zhou G; Liu F; Cong Y; Liu Z
Clin Exp Immunol; 2017 Mar; 187(3):428-440. PubMed ID: 27921309
[TBL] [Abstract][Full Text] [Related]
56. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
57. News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010.
Latella G; Fiocchi C; Caprili R
J Crohns Colitis; 2010 Dec; 4(6):690-702. PubMed ID: 21122584
[TBL] [Abstract][Full Text] [Related]
58. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.
Su J; Chen T; Ji XY; Liu C; Yadav PK; Wu R; Yang P; Liu Z
Inflamm Bowel Dis; 2013; 19(4):720-8. PubMed ID: 23429464
[TBL] [Abstract][Full Text] [Related]
59. Research Progress of Interleukin-27 in Inflammatory Bowel Disease.
Wang Q; Chen F; Peng Y; Yi X; He Y; Shi Y
Inflamm Bowel Dis; 2024 Feb; 30(2):303-310. PubMed ID: 37540894
[TBL] [Abstract][Full Text] [Related]
60. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification.
Isaacs KL; Sartor RB; Haskill S
Gastroenterology; 1992 Nov; 103(5):1587-95. PubMed ID: 1426879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
